Radiotherapy during pregnancy for clinical stages IA–IIA Hodgkin's disease

Woo, Shiao Y.; Fuller, Lillian M.; Cundiff, Jackson; Bondy, Melissa L.; Hagemeister, Fredrick B.; McLaughlin, Peter; Velasquez, William S.; Swan, F.; Rodriguez, Maria Alma; Cabanillas, Fernando; Allen, Pamela K.; Carpenter, Robert J.

doi:10.1016/0360-3016(92)90761-6

Cited by 122 publications

(58 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There seems to be no evidence for teratogenic effect of local treatment with supradiaphragmatic radiotherapy, especially in early trimesters, or chemotherapy, mainly given during the second or third trimester of pregnancy [29].…”

Section: Treatment and Outcomementioning

confidence: 99%

See 1 more Smart Citation

Coexistence of Pregnancy and Malignancy

Pavlidis¹

2002

The Oncologist

316

250

View full text Add to dashboard Cite

Cancer complicating pregnancy is a rare coexistence. The incidence is approximately 1 in 1,000 pregnancies. The most common cancers are those more frequently seen during the reproductive age of a woman. Breast cancer, cervical cancer, Hodgkin's disease, malignant melanoma, and leukemias are the most frequently diagnosed malignancies during gestation.The diagnostic and therapeutic management of the pregnant patient with cancer is especially difficult because it involves two persons, the mother and the fetus.In this paper we review: A) the therapeutic and diagnostic management of these patients; B) the safety of diagnostic and therapeutic procedures; C) the metastatic pattern of the maternal tumors to the placenta and fetus, and D) the potential recommendations for therapeutic abortion.

show abstract

Section: Treatment and Outcomementioning

confidence: 99%

“…Among 775 women with stage IA-IIA Hodgkin's disease treated with radiotherapy, 3.2% were pregnant [29]. Non-Hodgkin's lymphoma (NHL) occurring in pregnancy is more rare.…”

Section: Epidemiologymentioning

confidence: 99%

Coexistence of Pregnancy and Malignancy

Pavlidis¹

2002

The Oncologist

316

250

View full text Add to dashboard Cite

show abstract

“…The remaining studies found little, if any, detrimental effect on birth outcome among women capable of becoming pregnant (Andrieu and Ochoa-Molina, 1983;Aisner et al, 1993;Brierley et al, 1998). Likewise, a few case series found normal birth outcome in women diagnosed with HD during or shortly after pregnancy (Woo et al, 1992;Anselmo et al, 1999;Aviles and Neri, 2001). …”

mentioning

confidence: 98%

Hodgkin's disease and birth outcome: a Danish nationwide cohort study

et al. 2007

View full text Add to dashboard Cite

In a Danish nationwide cohort study of 292 births from 1973 to 2002 in women with Hodgkin's disease (HD), we compared birth outcome with 14 042 births from a cohort of mothers without cancer. We found no substantially increased risk of preterm birth, low birth weight at term, or stillbirth and no difference in proportion of male newborns for 192 children of women with HD before pregnancy. The prevalence odds ratio (POR) for congenital abnormalities was 1.7 (95% confidence interval (CI): 0.9 -3.1). Among 15 newborns of mothers diagnosed during pregnancy, the POR of preterm birth was 26.6 (95% CI: 8.5 -83.0), but five out of the eight preterm deliveries among these women were elective. We found no substantially increased risk of adverse birth outcome among 85 newborns of women diagnosed within 2 years postpartum, though effect estimates were imprecise. The overall findings are reassuring, they cannot exclude the possibility of an increased risk of congenital abnormalities for newborns of women diagnosed with HD before pregnancy.

show abstract

“…Despite HL is the most frequent hematological cancer complicating pregnancy data on its management are still scanty. There are reports published before 1992 using combination of mustargen, vincristine, procarbazine and prednisone (MOPP regimen) and small series of more recently treated patients, but they markedly differ from each other in site, stage of disease and in period of gestation (1, 3, 33, 53, 54, 57-61 54). Single agent AC such as vinblastine has been reported to allow healthy offspring and favorable outcome to mothers (33).…”

Section: Hodgkin Lymphomamentioning

confidence: 99%

Antiblastic Treatment and Haematological Malignancies during Pregnancy: A Crucial Decision

Michieli

Peccatori

Lleshi

et al. 2012

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Antiblastic treatment of hematological malignancies during pregnancy poses a number of issues related to the curability of the maternal disease, the need of a prompt treatment and the potential toxicity of chemotherapy for the fetus. Here we report the results of a systematic literature search about the management of the most frequent hematological malignancies that may occur during pregnancy, focusing on specific issues related to gestational age at diagnosis, fetal toxicity and efficacy on the maternal side. The standard approach in non-pregnant women is illustrated as reference.

show abstract

Radiotherapy during pregnancy for clinical stages IA–IIA Hodgkin's disease

Cited by 122 publications

References 11 publications

Coexistence of Pregnancy and Malignancy

Coexistence of Pregnancy and Malignancy

Hodgkin's disease and birth outcome: a Danish nationwide cohort study

Antiblastic Treatment and Haematological Malignancies during Pregnancy: A Crucial Decision

Contact Info

Product

Resources

About